Biotech innovator Syntis Bio has secured $38 million in Series A funding, positioning the company to dramatically reshape the treatment landscape for obesity, diabetes, and rare metabolic disorders. By turning complex injectable therapies into easy-to-take oral pills, Syntis Bio aims to unlock access and improve outcomes for millions of patients globally.

This milestone round included notable investors such as Cerberus Ventures, Mansueto Investments, Woori Venture Partners US, Apollo Labs, BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures, and Cerity Partners Ventures.

The End of Injections for Chronic Diseases

For decades, patients suffering from chronic diseases like type 2 diabetes or severe obesity have been tethered to injections and invasive delivery methods. These approaches, while effective, often come with significant challenges: poor adherence, higher risk of complications, and reduced quality of life.

Syntis Bio’s breakthrough platform seeks to change this entirely. Their proprietary oral delivery technology harnesses the power of the small intestine - the body’s natural hub for nutrient absorption and metabolic signaling. By delivering complex biologics directly to this “control center,” the company is creating pills that can replace needles and infusion centers with a single daily dose.

Building on Biology, Not Fighting It

Rather than forcing drugs into the body in ways it resists, Syntis Bio’s approach works with human biology. Their platform protects fragile therapeutic molecules as they pass through the harsh gastric environment, allowing them to reach the small intestine intact and be absorbed as nature intended.

What’s particularly striking here - and what every founder can learn from - is Syntis Bio’s choice to focus not just on engineering the molecule or the pill, but on understanding and leveraging the systemic pathways inside the human body. Many healthtech startups get stuck optimizing external devices, wearables, or digital nudges. Syntis Bio went deeper: they found the true leverage point within our own anatomy and biology, then built their solution around that core truth.

Here lies a critical founder insight: when you understand the deep system dynamics - whether in the body, a supply chain, or a digital ecosystem - you can create solutions that feel almost inevitable in hindsight. Rather than layering on patches or superficial enhancements, you design from the inside out. This strategy doesn’t just lead to better products; it leads to market dominance because your solution becomes the obvious choice. Once a patient can switch from injections to a simple pill without sacrificing efficacy, there’s no going back - and that’s the ultimate competitive moat.

Massive Market Opportunity

The scale of Syntis Bio’s potential impact is enormous. The obesity treatment market alone is projected to surpass $100 billion by 2030, while diabetes therapies are expected to cross $140 billion. Adding rare metabolic and endocrine disorders magnifies this potential even further.

Syntis Bio’s early data from preclinical and initial human studies show excellent safety and bioavailability, demonstrating the feasibility of delivering large therapeutic molecules through an oral route. This proof of concept paves the way for a new era in metabolic treatment, shifting therapy from clinic-based interventions to patient-centered, at-home management.

The $38M Series A: Fueling Next-Stage Growth

The newly raised $38 million will accelerate clinical development of Syntis Bio’s lead programs for obesity and type 2 diabetes, expand its pipeline to include rare diseases, and scale up manufacturing capabilities. This capital also supports the recruitment of additional world-class scientists, clinical experts, and operational leaders to drive upcoming trials and strategic partnerships.

A Mission-Driven Team

Under the leadership of CEO Rahul Dhanda, Syntis Bio has assembled a team that blends deep scientific expertise with commercial execution. The company is built around the belief that treatment shouldn’t add to the patient’s burden - it should remove it. By combining advanced biology, chemistry, and delivery science, they’re building therapies that meet patients where they are, not where the healthcare system expects them to be.

Beyond the Pipeline: A Paradigm Shift

Beyond their immediate programs, Syntis Bio’s proprietary gut-targeting delivery platform has broader potential applications. From immunology to oncology, the ability to turn injectable therapies into pills opens doors across multiple therapeutic areas. This modular approach enables partnerships with pharmaceutical companies looking to improve patient adherence and expand access globally.

Looking Ahead

Syntis Bio is preparing to enter pivotal clinical trials in the next 18 to 24 months. With their science validated in early studies and a strong financial runway secured, they’re positioned to deliver on their promise of making advanced therapeutics simpler, more humane, and more accessible.

By proving that it’s possible to move from injection to pill without compromising efficacy, Syntis Bio isn’t just improving individual therapies - it’s setting a new standard for what patients and providers should expect.

A New Era for Patients and Founders Alike

Syntis Bio’s $38 million Series A funding signals a future where treating complex chronic and rare diseases no longer means needles and infusions. Their patient-first approach, rooted in a deep understanding of biology, offers a powerful blueprint for founders: don’t just fix surface-level pain points - go to the source, build from the core, and create solutions that change behaviors by making the best option the easiest one.